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ABSTRACT 
Ocular Drug Delivery has been a major challenging and interesting field for the pharmaceutical scientist due to unique anatomy and physiology 
of eye. The eye suffers from various problems like glaucoma, dry eye syndrome, keratitis, endopthalmitis, trachoma and conjunctivitis. To 
achieve the effective ocular therapy within the eye. An adequate amount of active ingredients must be delivered and maintaine d at the site of 
action. The conventional therapy exhibits the poor bioavailability due to the rapid precorneal drug loss. There are some static and dynamic 
barriers which also affect the bioavailability of drug. There are considerable efforts which are directed towards newer drug system for ocular 
administration to overcome the drawbacks of conventional therapy. The use of in situ overcomes the problems when drop instilled into the eye 
it undergoes sol-gel transition and transition form in cul-de-sac. This review involves in-situ gel system which includes thermally triggered 
system, pH triggered system and ion cross linking system. It involves detailed method of preparation and evaluation parameters of pH triggered 
system. 
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The eye is a sensory organ that converts light to an electric 
signal that is treated and interpreted by the brain.1 Eye is 
vital and delicate organ of the body and delivering drug into 
eye is most complicated task as it offers the numerous 
protective mechanisms that are present in the eye to shield it 
from various foreign particles.2 Ophthalmic delivery system 
is a challenging area for the formulation chemist due to 
unique anatomy and physiology of the eye. The anatomy and 
physiology of the eye render this organ delicately impervious 
to foreign substances. The challenge to the formulator is to 
avoid the protective barriers of the eye without causing 
permanent tissue damage.3 There are many eye diseases 
which can be affected to the eye and also eye vision. 
Therefore marketed ophthalmic dosage formulations are 
classified as conventional and non-conventional drug 
delivery systems. There are most commonly existing 
ophthalmic preparations such as drops and ointments about 
70% of the eye dosage formulations are in market. But these 
formulation when instilled into eye they are rapidly drained 
away from the ocular surface due to blinking, tear flow and 
lacrimal nasal drainage of the eye. Only a small amount of 
drug is available for its therapeutic effect ensuing in frequent 
dosing application to the eye. So to overcome these problems 
newer pharmaceutical ophthalmic formulation such as in-
situ gel, nanoparticle, liposome, nano suspension, micro 
emulsion, intophoresis and ocular inserts have been 
established in last three decades to increase the 
bioavailability of the drug in a sustained and controlled 
manner.4 
ANATOMY OF EYE 
The human eye is divided into two important segments i.e. 
anterior segment which involves the cornea, conjunctiva, iris, 
pupil, ciliary body, anterior chamber, aqueous humor, lens 
and trabecular meshwork and the posterior segment 
includes vitreous humor, sclera, retina, choroid, macula and 
optic nerve. The outermost membrane of the eye is cornea it 
is a clear, transparent, thin vascular tissue that is composed 
of five layers: epithelium, bowmans‘s layer, stroma, 
Descemet‘s membrane and endothelium. Aqueous humor 
consists of clear liquid that fills both the posterior and 
anterior chambers of the eye. It is major source of nutrition 
for the cornea.5 The iris is a thin circular contractile curtain 
located in front of the lens but behind the cornea it is a 
diaphragm of variable size whose function is to adjust the 
size of the pupil to regulate the amount of light admitted into 
the eye and adjust with the help of iris sphincter and dilator 
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muscle. The ciliary muscle is a ring of smooth muscles in the 
eye’s middle layer that controls space for observing objects 
at varying distances. The lens is a transparent biconvex 
structure encased in a thin transparent covering shape of the 
lens. It is a flexible unit consisting of layers of tissue enclosed 
in a capsule. It is deferred from the ciliary muscles by very 
thin fibers called the zonules. The conjunctiva is a mucous 
membrane that begins at the edge of the cornea and lines the 
inside surface of the eyelids and sclera upto limbus. It 
provides protection to the eyes by secreting mucus that 
prevents entry of microorganisms and lubricating the eyes. 
The sclera is protective outer layer of the eye referred to as 
the “white of the eye” and it maintains the shape of the eye. It 
acts as a principal protection to the internal organs. The 
sclera is juxtaposed by a highly vascularized tissue known as 
the choroid which is sandwiched between the retina and 
sclera. The choroid is a thin highly vascular membrane that is 
dark brown in colour and contains a pigment that absorbs 
excess light and so prevents blurred vision it is the second 
layer of the eye and lies between the sclera and the retina. It 
contains the blood vessels that provide nourishment to the 
outer layers of the retina. The retina is a multiple layers and 
complex structure that consists of vascular glial and neural 
cells and nerve fibers. It is located at the back of the human 
eye. It is a light-sensitive structure which contains 
photosensitive cells that capture light rays and convert them 
into electrical impulses. These impulses travel along the 
optic nerve to the brain, where they are converted into 
images. The vitreous humour is smaller section in front 
which contains water like transparent thin-jelly-like 
substance that is distributed between retina and lens.5,8,9 
 
 
   
Figure 1: Anatomy of the human eye 
 
MODE OF DRUG ADMINISTRATION TO EYE 
A successful design of a drug delivery system therefore 
requires a combined knowledge of the drug molecule. There 
are some possible routes of drug delivery into the ocular 
tissues. The selection of the route of administration of drug 
depends primarily on the target tissue. A significant 
challenge to the formulator is to bypass the protective 
barriers of the eye without causing permanent tissue 
damage. Ophthalmic drug delivery is used only for the 
treatment of local conditions of the eye and cannot be used 
as a entry of a drug into the systemic circulation. 
Conventional ophthalmic formulations like solution, 
suspension and ointment have several disadvantages which 
effect into poor bioavailability of drug in the ocular cavity. 
Ideal ophthalmic drug delivery must be able to sustain the 
drug release and to remain in the front area of the eye for 
prolong period of time.(1,2) The bioavailability of traditional 
ocular drug delivery systems such as eye drops is very poor 
because the eye is protected by a series of complex defense 
mechanisms that make it tough to achieve an effective drug 
concentration within the target area of the eye. The anatomy 
physiology of the eye is one of the most complex and unique 
systems in the human body. Lachrymation, effective 
drainage by the nasolacrimal system the inner and outer 
blood-retinal barrier the impermeability of the cornea and 
inability of absorption by other non-corneal structures cause 
the eye to be impervious to foreign substances. While these 
innate barriers are advantageous for delaying the invasion of 
undesired molecules pathogens and particulates they pose 
significant challenges to delivering ocular drugs.10 Some 
routes of administration of the drug to the are given below. 
(Figure 2)  
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Figure 2: Routes of Administration of drug into Eye        
                                                                                                                    
1. Topical Administration 
Topical ocular drug administration is skilled by eye drops 
but they have only a short contact time on the eye surface. 
The contact and thereby duration of drug action can be 
prolonged by formulation design that is by gels, gellifying 
formulations, ointments and insert. It is the most commonly 
used route of drug administration for most of the drugs that 
are topically applied. The site of action is typically different 
layers of the cornea, conjunctiva, sclera and the other tissues 
of the anterior segment such as the iris and ciliary body. 
Upon administration precorneal factors and structural 
barriers negatively affect the bioavailability of topical 
formulations. Precorneal factors comprise solution drainage, 
blinking, tear film, tear turn over and induced lacrimation. 
Viscosity is another factor that can regulate nonproductive 
absorption and ocular absorption. Increasing viscosity may 
decrease drainage rate, prolong precorneal residence time 
and increase ocular absorption.7,10 
2. Oral Administration 
Oral delivery alone or in combination with topical delivery 
has been studied for different reasons. Topical delivery 
failed to produce therapeutic concentrations in the posterior 
segment. Also oral delivery was studied as a patient 
preferred route to treat chronic retinal diseases as 
compared to the parenteral route. However limited 
availability too many of the targeted ocular tissues bounds 
the utility of oral administration which requires high dosage 
to achieve important therapeutic efficacy. Such doses can 
result in systemic side effects. Hence parameters such as 
safety and toxicity need to be measured when trying to 
obtain a therapeutic response in the eye upon oral 
administration.7 
3. Systematic Administration 
Following systemic administration the blood-aqueous 
barrier and blood-retinal barrier are the major barriers for 
the anterior segment and posterior segment of the ocular 
drug delivery. Due to the presence of blood retinal barrier 
systemic administration has achieved a limited success to 
deliver drugs to the vitreo-retinal tissues. This route of 
administration may also result in non-specific binding of 
drug to other tissues and cause systemic cytotoxicity. Only 1-
2% of plasma drug concentration is achieved in the vitreous 
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humor and therefore requires frequent administration to 
maintain therapeutic drug level. Even though it is ideal to 
deliver the drug to the retina through systemic 
administration it is still a challenge because of the blood-
retina barrier which strictly regulates drug permeation from 
blood to the retina. Hence specific intravenous targeting 
systems are needed to conveyance molecules through the 
choroid into deeper layers of the retina.10 
4. Intravitreal Administration 
The entry of drug straight into the vitreous and retina can be 
achieved by administrating drug directly into the vitreous. 
Small molecules are able to diffuse rapidly in the vitreous 
but the movement of large molecules particularly positively 
charged is restricted. The delivery from the vitreous to the 
choroid is more complicated due to the hindrance by the 
RPE (Retinal Pigment Epithelium) barrier. Distinct other 
routes intravitreal injection carries higher drug 
concentrations to the vitreous and retina. Drug distribution 
in the vitreous is nonuniform .This is also depends on the 
pathophysiological condition and molecular weight of the 
administered drug. Longer retention time and higher 
vitreous concentration of drugs was obtained following this 
route of administration.1,2,10 
THE BARRIERS 
I. Drug Loss from the Ocular Surface    
After instillation the flow of lacrimal fluid removes instilled 
compounds from the surface of the eye. Routes of drug 
kinetics refer to following processes: 
1) Transcorneal permeation into the anterior chamber from 
lachrymal fluid. 
2) Non-corneal drug permeation through the conjunctiva 
and sclera into the anterior uvea. 
3) Drug distribution from the blood stream via blood-
aqueous barrier into the anterior chamber. 
4) Elimination of drug from the anterior chamber to the 
aqueous humor turnover to the trabecular meshwork and 
Sclemm's canal.  
5) Drug removal from the aqueous humor into the systemic 
circulation across the blood-aqueous barrier. 
6) Drug distribution from the blood into the posterior eye 
across the blood-retina barrier and intravitreal drug 
administration. 
7) Drug elimination from the vitreous via posterior route 
across the blood-retina barrier.  
8) Drug elimination from the vitreous via anterior route to 
the posterior chamber.  
Though the lacrimal turnover rate is only about 1 μl/min the 
excess volume of the instilled fluid goes to the nasolacrimal 
duct rapidly in a couple of minutes. Another cause of non-
productive drug removal is its systemic absorption instead 
of ocular absorption. Systemic absorption may take place 
either directly from the conjunctival sac via local blood 
capillaries or after the solution flow to the nasal cavity.13 
II. Lacrimal Fluid Barriers 
Corneal epithelium confines drug absorption from the 
lacrimal fluid into the eye. Mature epithelial cells forms 
corneal barrier from the limbal region they migrate towards 
the center of the cornea and to the apical surface. The 
corneal epithelial cells form tight connections that limit the 
paracellular drug permeation. Therefore lipophilic drugs 
have normally at least an order of magnitude higher 
permeability in the cornea than the hydrophilic drugs.1,2 
Despite the tightness of the corneal epithelial layer  
transcorneal permeation is the key route of drug entrance 
from the lacrimal fluid to the aqueous humor. In general the 
conjunctiva is more permeable epithelium than the cornea 
and its surface area is also nearly 20 times greater than that 
of the cornea. Absorption of the drug across the bulbar 
conjunctiva has gained increasing attention recently, since 
conjunctiva is fairly permeable to the hydrophilic and large 
molecules. Therefore, for larger bio-organic compounds such 
as proteins and peptides it may serve as a route of 
absorption.2 
III. Blood- Occular Barriers 
The eye is protected from the xenobiotics in the blood 
stream by blood-ocular barriers. These barriers have two 
types: blood-aqueous barrier and blood-retina barrier. The 
anterior blood-eye barrier is composed of the endothelial 
cells in the uvea it is the middle layer of the eye beneath the 
the sclera. It consists of the iris, ciliary body and choroid. 
This barrier prevents the access of hydrophilic drugs and 
plasma albumin into the aqueous humor. The posterior 
barrier between blood stream and eye is involved of retinal 
pigment epithelium (RPE) and the tight walls of retinal 
capillaries. Inflammation may interrupt the integrity of this 
barrier causing the unlimited drug delivery to the anterior 
chamber. In fact the permeability of this barrier is poorly 
categorized. Unlike retinal capillaries the vasculature of the 
choroid has wide blood flow and leaky walls. Drugs easily 
gain access to the choroidal extravascular space but after 
that distribution into the retina is limited by the RPE and 
retinal endothelia. Despite its high blood flow the choroidal 
blood flow establishes only a minor fraction of the entire 
blood flow in the body. Unlike blood brain barrier the blood-
eye barriers have not been considered in terms of drug 
transporter and metabolic enzyme expression.1,2,13 
Classification of Ocular Drug Delivery System:  
Ocular drug deliveries consist of following types of dosage 
forms: 
1). Semisolid -Gel, Ointment.  
2). Solid -Ocular Inserts.  
3). Liquid – Solution, Suspension. 
4). Intraocular –Implant, Injections. 
Types of Ocular Gel 
I. Organogel 
II. Hydrogel  
Advantages of Ocular In-situ Hydrogel 
I. Reduced dose concentration.  
II. Reduced dosing frequency.  
III. Improved patient acceptability.  
IV. Generally more comfortable than insoluble or soluble 
insertion.  
V. Increased bioavailability due to-  
a. Increased precorneal residence time.  
b. Decreased nasolacrimal drainage of the drug  
VI. Chances of undesirable side effects arising due to 
systemic absorption of the drug through naso-lacrimal duct 
are reduced.  
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VII. Easy to manufacture and hence less complex process 
and reduces cost of Manufacturing.6,11 
Disadvantages of Ocular In-situ Hydrogel   
I. Blurred vision. 
II. Difficulty in self-insertion.  
III. Matted eyelids.  
IV. Limited values in terms of improvement of 
bioavailability.16,19 
Classification of In Situ Gel 
1. Based on physical stimuli. 
a. Thermally Triggered System. 
b. pH Triggered System. 
2. Based on physical mechanism 
a. Swelling. 
b. Diffusion. 
3. Based on chemical reaction 
a. Ion Cross Linking. 
b. Enzymatic Cross Linking. 
c. Photo- Polymerisation.  
In-Situ formation based on physiological stimuli 
a. Thermally Trigged System 
Temperature-sensitive hydrogels are possibly the most 
commonly studied class of environment-sensitive polymer 
systems in drug delivery research. The use of biochemical 
whose transitions from sol-gel is triggered by increase in 
temperature is a smart way to approach in-situ formation. In 
this system gelling of the solution is triggered by change in 
temperature thus satisfying the drug release. These 
hydrogels are liquid at room temperature (20–25 °C) and 
undergo gelation when in contact with body fluids (35– 37 
°C) due to an increase in temperature. The ideal critical 
temperature range for such system is ambient and 
physiologic temperature such that clinical manipulation is 
facilitate and no external source of heat other than that of 
body is required for trigger gelation. A useful system should 
be tolerable to account for small differences in local 
temperature such as might be encountered in additions at 
the surface of skin or in the oral cavity. Three main 
strategies are occurs in engineering of thermo responsive 
sol-gel polymeric system. The temperature-sensitive 
hydrogels are classified into negatively thermo sensitive, 
positively thermo sensitive and thermally reversible 
gels.(2,3,13)Negative temperature-sensitive hydrogel have a 
lower critical solution temperature (LCST) and contract 
upon heating below the LCST. Polymers with low critical 
temperature (LCST) transition between ambient and 
physiologic temperature is used for this resolve. One of the 
most extensively investigated polymers that exhibit useful 
LCST transition is poly (N-isopropyl acrylamide) 
(PNIPAAm). A positive temperature sensitive hydrogel has 
upper critical solution temperature (UCST) such hydrogel 
contracts upon cooling below the UCST. Polymer networks 
of poly (acrylic acid) (PAA) and polyacrylamide (PAAm) or 
poly (acryl amide-co-butyl methacrylate) have positive 
temperature required of swelling. The most commonly used 
thermo reversible gels are these prepared from poly 
(ethylene oxide)-b-poly (propylene oxide)-b-poly (ethylene 
oxide) (Pluronics®, Tetronics®, poloxamer). Polymer 
solution is a free flowing liquid at require temperature and 
gels at body temperature. Novel “protein polymers” called as 
ProLastins which undergo an irreversible sol gel transition 
when injected as a solution into the body the material forms 
a firm stable gel within minutes. It remains at the site of 
injection providing absorption times from less than one 
week to many months. Such a system would be easy to 
administer into desired body cavity. 13 
b. pH Triggered Systems  
Another formation of in situ gel based on physiologic stimuli 
is formation of gel is made by pH changes. In this system 
gelling of the solution is triggered by a change in pH. At pH 
4.4 the formulation is a free flowing solution which 
undergoes coagulation when the pH is raised by the tear 
fluid to pH 7.4. The pH change of about 2.8 units after 
instillation of the formulation pH4.4 into the tear film leads 
to an almost rapid transformation of the highly fluid latex 
into a viscous gel.  All the pH-sensitive polymers contain 
dependant acidic or basic groups that accept or release 
protons in response to changes in environmental pH. The 
polymers with a great number of ionizable groups are 
known as polyelectrolytes. Swelling of hydrogel increases as 
the exterior pH increases in case of weakly acidic (anionic) 
groups but decreases if polymer contains weakly basic 
(cationic) groups. The most of anionic pH sensitive polymers 
are based on PAA (Carbopol®, carbomer) or its derivatives. 
Likewise poly vinyl acetal diethyl amino acetate (AEA) 
solutions with a low viscosity at pH 4 form hydrogel at 
neutral pH condition. Drug formulated in liquid solutions 
have several limitations including bioavailability and 
partiality to be easily distant by tear fluid. To minimize this 
factors and exploit this drug delivery by making a 
poly(acrylic acid) (PAA) solution that would be gel at pH 7.4 
by that we found that at concentrations high  to cause 
gelation however the low pH of PAA solution would cause 
damage to surface of eye before being neutralized by the 
lacrimal fluid. This problem was solved by partially by 
combining PAA with HPMC a viscous enhancing polymer 
which resulted in pH responsive polymer mixtures that was 
solution at pH 4 and gel at pH 7.4. Mixtures of poly 
(methacrylic acid) (PMA) and poly (ethylene glycol) (PEG) 
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Method of preparation (pH triggered method) 
 
Figure 3: Method of Preparation 
 
In Situ formation based on physical mechanism 
a. Swelling 
In situ gel formation material absorbs water from 
surrounding environment and expands to desired space. One 
such substance is myverol 18-99 (glycerol mono-oleate) 
which is polar lipid that swells in water to form lyotropic 
liquid crystalline phase structures. It has some bioadhesive 
properties and can be degraded invivo by enzymatic 
action.21,23 
b. Diffusion 
This method involves the diffusion of solvent from polymer 
solution into adjacent tissue and results in precipitation of 
polymer matrix. N methyl pyrrolidone (NMP) has been 
shown to be a suitable solvent for such system.14,21 
In Situ formation based on chemical reaction 
Chemical reactions that results in situ gelation may involve 
precipitation of inorganic solids from supersaturated ionic 
solutions, enzymatic processes and photo-initiated 
processes.20 
a. Ionic Cross Linking 
Polymers may undergo phase transition in existence of 
several ions. Some of the polysaccharides fall into the class of 
ion-sensitive ones.20 While k-carrageenan forms rigid, fragile 
gels in account of small amount of K+, i-carrageenan forms 
flexible gels mainly in the presence of Ca2+. Gellan gum 
economically available as Gelrite® is an anionic 
polysaccharide that goes through in situ gelling in the 
presence of mono and divalent cations, including Ca2+, 
Mg2+, K+ and Na+. Gelation of the low methoxy pectins can 
be caused by divalent cations that are Ca2+. Likewise alginic 
acid goes through gelation in presence of divalent/polyvalent 
cations. Example Ca2+ due to the contact with guluronic acid 
block in alginate chains.21 
 
 
b. Enzymatic Cross Linking 
In Situ formation catalysed by natural enzymes has not been 
considered widely but appears to have some advantages 
over chemical and photochemical approaches. For example, 
an enzymatic process works efficiently under physiologic 
conditions without need for potentially harmful chemicals 
such as monomers and initiators. Intelligent stimuli-
responsive delivery systems using hydrogels that can release 
insulin which have been investigated. Cationic pH-sensitive 
polymers containing immobilized insulin and glucose 
oxidase can swell in response to blood glucose level releasing 
the entrapped insulin in a pulsatile fashion. Adjusting the 
amount of enzyme also provides a appropriate mechanism 
for controlling the rate of gel formation which allows the 
mixtures to be injected before gel formation.20,21 
c. Photo – Polymerization 
Photo-polymerisation is commonly used for in situ formation 
of biomaterials. A solution of reactive macromer and initiator 
can be injected into a tissues site and the use of 
electromagnetic radiation to form gel. Acrylate or related 
polymerizable functional groups are normally used as the 
individual monomers and macromers because they rapidly 
undergo photo-polymerisation in the existence of suitable 
photoinitiator. Typically long ultraviolet and visible 
wavelengths are used. Short wavelength ultraviolet is not 
used often because it has partial penetration of tissue and 
biologically harmful. A ketone such as 2,2 dimethoxy-2-
phenyl acetophenone, is often used as the initiator for 
ultraviolet photo-polymerization while camphorquinone and 
ethyl eosin initiators are often used in visible light systems. 
These systems can be designed readily to be degraded by 
chemical or enzymatic processes for long term persistence in 
vivo. Photo polymerizable systems when introduced to the 
desired site through injection get photo cured in situ with the 
help of fiber optic cables and then release the drug for 
prolonged period of time. The photo-reactions provide fast 
polymerization rates at physiological temperature. 
Furthermore, the systems are easily located in complex 
shaped volumes leading to an implant formation.13,21 
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In Situ Gelling Polymers 
A polymer is a macromolecule composed of repeating 
structural units and these subunits are connected by 
covalent chemical bonds. 
Ideal Characterstics of Polymers  
1. It should be biocompatible.  
2. It should be capable of adherence to mucus and non 
irritating.  
3. It should have pseudo plastic behaviour.  
4. It should influence the tear behaviour.  
5. The polymer should be capable of decrease the viscosity 
with increasing shear rate there by offering lowered 
viscosity during blinking & stability of the tear film during 
fixation. 13,23 
POLYMERS USED AS IN SITU GELLING AGENTS ARE 
1. Gellan gum 
2. Alginic gum 
3. Carbomer 
4. Pluronic F127 
5. Xylogulan 
6. Pectin 
7. Xanthum Gum 
8. Chitosan 
Carbomer  
Carbomer is a high molecular weight, cross linked 
polyacrylic acid derivative and has strong mucoadhesive 
property. It is aqueous soluble vinyl polymer. In aqueous 
solution it shows sol to gel transition when the pH is raised 
above its pKa of about 5.515. As the concentration of 
carbomer increases its acidic nature may lead to irritation to 
eye. Addition of cellulose will reduce polymer concentration 
and will improve gelling property. Different grades of 
carbomer are present in market which includes carbopol 
934(lowest cross linking density), carbopol 940 (highest 
cross linking density) and carbopol 981 (intermediate cross 
linking density). Carbopol is used as gelling, emulsifying and 
suspending agents. Carbopol are in compatible with cationic 
polymers, strong acids, high level of electrolytes and they 
swell in water 1000 times when exposed to water to form 
gelation pH of 4-6 do not dissolve in water.13 
EVALUATION PARAMETERS 
1. Physical Appearance:  
Physical appearance of formulation was visually observed. 
2. pH: 
pH affects both solubility as well as stability of drug in 
ophthalmic formulations. It should be such that the 
formulation will remain stable at that pH. The pH of the 
prepared in situ gelling system after addition of all the 
ingredients will be measured using pH meter.13 
3. Clarity: 
The clarity of the formulations before and after gelling will 
be determined by visual inspection of prepared in situ 
formulation is checked in presence of any particulate matter 
under fluorescent light against a white and black 
background. 12,13 
3. Gelling Capacity Test: 
Gelling capacity of prepared formulation is determine by 
placing the drop of formulation into a test tube containing 
2.0 ml of pH 7.4 freshly prepared simulated tear fluid (STF) 
equilibrated at 35±1◦C and visually observed. The time 
taken for gelling was noted.29 
4. Drug Content: 
It is determined by taking 1ml of the formulation and 
diluting it to 100ml with distilled water. 1 ml was withdrawn 
and further diluted to 10 ml with distilled water. 
Concentration was determined at 200-400nm by using UV 
visible spectroscopy.13 
5. Viscosity: 
Viscosity measures the resistance of a solution to flow when 
a stress is applied. It is an important factor in determining 
residence time of drug in the eye. The solutions were allowed 
to gel in the STF and then viscosity measurements can be 
calculated by using Brookfield viscometer. The In situ gel 
formulation was placed in sampler tube. The angular velocity 
ran from 10-100 rpm. Viscosity of the formulations increases 
with increases in the polymer concentration. The hierarchy 
of shear rate was reversed and average of two readings was 
used to calculate the viscosity. The samples are analysed at 
room temperature at 25 °C.26 
6. In-vitro Release Studies: 
In vitro drug release study of In-situ gel solution was carried 
by using Franz diffusion cell. Formulation placed in donor 
compartment and freshly prepared stimulated tear fluid in 
the receptor compartment. Between donor and receptor 
dialysis membrane is placed .Then whole assembly is placed 
in thermostatically controlled magnetic stirrer. The 
temperature of medium was maintained at 37 °c ±0.5 °c. 1 ml 
of sample is withdrawn at predetermine time interval of 1 
hour to 6 hour and same volume of fresh is replaced. The 
withdrawn sample is diluted to 10 ml of volumetric flask 
with respective solvent and analysed by UV 
spectrophotometer.30 
7. Accelerated Stability Studies: 
A stability study for in situ formulation is carried out as per 
ICH guidelines to determine the physical stability of the 
formulation under accelerated storage conditions. All the 
formulation were analyzed for visual appearance, clarity, pH 
and drug remaining for 6 weeks of stability studies.23 
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